NASDAQ:ABVX - Nasdaq - US00370M1036 - ADR - Currency: USD
71.945
+0.17 (+0.24%)
The current stock price of ABVX is 71.945 USD. In the past month the price increased by 803.83%. In the past year, price increased by 501.04%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.43 | 344.84B | ||
AMGN | AMGEN INC | 14.3 | 159.64B | ||
GILD | GILEAD SCIENCES INC | 14.62 | 140.79B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.67B | ||
REGN | REGENERON PHARMACEUTICALS | 12.25 | 60.34B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 52.39B | ||
ARGX | ARGENX SE - ADR | 72.69 | 41.24B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.68 | 32.36B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.80B | ||
INSM | INSMED INC | N/A | 20.62B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.10B | ||
BIIB | BIOGEN INC | 8.24 | 19.33B |
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
ABIVAX SA-ADR
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
The current stock price of ABVX is 71.945 USD. The price increased by 0.24% in the last trading session.
The exchange symbol of ABIVAX SA-ADR is ABVX and it is listed on the Nasdaq exchange.
ABVX stock is listed on the Nasdaq exchange.
13 analysts have analysed ABVX and the average price target is 31.51 USD. This implies a price decrease of -56.2% is expected in the next year compared to the current price of 71.945. Check the ABIVAX SA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABIVAX SA-ADR (ABVX) has a market capitalization of 5.41B USD. This makes ABVX a Mid Cap stock.
ABIVAX SA-ADR (ABVX) currently has 69 employees.
The Revenue of ABIVAX SA-ADR (ABVX) is expected to decline by -26.55% in the next year. Check the estimates tab for more information on the ABVX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABVX does not pay a dividend.
ABIVAX SA-ADR (ABVX) will report earnings on 2025-09-08.
ABIVAX SA-ADR (ABVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.68).
The outstanding short interest for ABIVAX SA-ADR (ABVX) is 2.45% of its float. Check the ownership tab for more information on the ABVX short interest.
ChartMill assigns a technical rating of 9 / 10 to ABVX. When comparing the yearly performance of all stocks, ABVX is one of the better performing stocks in the market, outperforming 99.8% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to ABVX. ABVX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ABVX reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 16.74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -85.88% | ||
ROE | -434.26% | ||
Debt/Equity | 1.29 |
ChartMill assigns a Buy % Consensus number of 88% to ABVX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -4.62% and a revenue growth -26.55% for ABVX